Editorial · Longevity · NAD+
NAD+ vs NMN in the UK: precursor or end-product
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Published Mon Jun 01 2026 01:00:00 GMT+0100 (British Summer Time) · 5 min read
NAD+ and NMN are not competing products: NMN (nicotinamide mononucleotide) is a precursor that the body converts into NAD+, the end-product co-enzyme. The practical reason supplements favour NMN is absorption: intact oral NAD+ is largely broken down in the gut, whereas NMN is absorbed and converted inside cells. The two also differ on regulation. Oral NAD+ sits under standard UK food-supplement rules, while NMN's status has been in flux: it is legal to sell in the UK as a food supplement, has a positive EFSA safety opinion, and is not yet formally authorised as a novel food in the EU. This is editorial, not medical advice.
“NAD+ vs NMN” is one of the most common searches in this category, and it slightly misframes the relationship. They are not rivals. This post explains how they fit together and where they genuinely differ. It is editorial commentary, not medical advice.
They are not competitors
NMN (nicotinamide mononucleotide) is a precursor. NAD+ (nicotinamide adenine dinucleotide) is the end-product co-enzyme your cells actually use. The body converts NMN into NAD+ through enzymatic steps inside cells. So the real question is not “which is better” but “which is the more practical thing to put in a capsule”, and that is mostly a question of absorption.
As covered in NAD+ supplements in the UK, intact oral NAD+ is poorly absorbed because much of it is broken down in the gut before it can be taken up. NMN is absorbed and then converted, which is why the supplement market centres on precursors rather than on NAD+ itself. That is the core reason you will see far more NMN products than NAD+ products on UK shelves.
What the evidence shows
Human trials of NMN indicate it can raise blood NAD+ markers and is generally well tolerated over the studied periods. That is consistent with its role as a precursor. What those raised markers translate to in terms of health outcomes is not established: studies suggest a biological effect, but there are no large long-term randomised trials demonstrating that NMN reverses ageing or treats any condition. The same evidence caution applies to NAD+ itself. Neither is a proven anti-ageing treatment.
Where regulation differs
This is the practical fork for a UK shopper. Oral NAD+ sold without medicinal claims sits under the Food Supplements (England) Regulations 2003 in the ordinary way. NMN’s status has been more eventful. It remains legal to sell in the UK as a food supplement, EFSA has issued a positive safety opinion on it, and it is not yet formally authorised as a novel food in the EU. That position has shifted since 2022 and is still moving, which is why we track it on the NMN sub-hub rather than fixing a status in this post.
The takeaway is not that one is “legal” and the other is not. Both are sold in the UK. The difference is that NMN carries an evolving novel-food question in the background that intact NAD+ does not.
How to choose between them
Because NMN is the more absorbable route to raising NAD+, most products built for that purpose use it or the related precursor NR. If you are choosing, the more useful comparison is often between the two precursors rather than between NMN and intact NAD+: see NR vs NMN. And whichever you consider, the label checklist in best NAD+ supplement UK applies.
We do not state doses. What studies have used is reported in general terms in the linked posts, alongside the framing that supplement choices should be discussed with a suitably qualified healthcare professional.
Read next
The NAD+ sub-hub maps every route and the NMN sub-hub goes deeper on the precursor. For the wider context, see NAD+ in the UK: the landscape explained.